Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease
NASHVILLE, Tenn., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into a definitive agreement to acquire TYRVAYA® (varenicline solution) nasal spray 0.03 mg from Viatris Inc., a global healthcare company. TYRVAYA is a cholinergic agonist indicated for the treatment of the signs and symptoms of dry eye disease (DED) and is currently approved in the U.S., China, and Taiwan, with marketing authorization applications pending in other countries.
Covered in this story
What has happened since
- Harrow Inc is down 28.8% since this was published, 75 days ago.
- Viatris is up 13.0% since this was published, 75 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $HROW yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Harrow Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.